CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗在 B 细胞淋巴系统恶性肿瘤患者中的当前挑战
英文原题：Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
查看英文原题
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种基于患者来源的基因工程T细胞的有前景的免疫疗法。CAR-T 细胞疗法的引入改变了B细胞淋巴系统恶性肿瘤患者的治疗模式。然而，挑战性问题仍然存在，包括管理CAR-T 细胞输注相关的危及生命的毒性，以及对CAR-T 细胞疗法的耐药导致疾病进展或复发。本综述总结了目前获批用于复发/难治性B细胞淋巴系统恶性肿瘤（包括淋巴瘤和骨髓瘤）患者的CAR-T 细胞疗法所面临的问题。我们重点关注CAR-T 细胞治疗后的独特毒性，如细胞因子相关事件和血液学毒性，以及CAR-T 细胞治疗后失败的机制。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy has changed the treatment paradigm of patients with B-cell lymphoid malignancies.
However, challenging issues including managing life-threatening toxicities related to CAR T-cell infusion and resistance to CAR T-cell therapy, leading to progression or relapse, remain. This review summarizes the issues with currently approved CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoid malignancies, including lymphoma and myeloma.
We focus on unique toxicities after CAR T-cell therapy, such as cytokine-related events and hematological toxicities, and the mechanisms underlying post-CAR T-cell failure.
论文信息
- 作者
- Kim SJ、Yoon SE、Kim WS
- 单位
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.South Korea
- 文献类型
- 综述
- 期刊
- Annals of laboratory medicine2024 May 1
- 原文标识
- PubMed 38205527 · DOI 10.3343/alm.2023.0388